DAX24.218 -0,3%ESt505.352 -0,1%Top 10 Crypto15,91 +1,5%Dow44.902 +0,5%Nas21.108 +0,2%Bitcoin99.936 -0,2%Euro1,1748 ±0,0%Öl68,39 -1,4%Gold3.336 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Volkswagen (VW) vz. 766403 Rheinmetall 703000 NVIDIA 918422 PUMA 696960 Deutsche Bank 514000 Tesla A1CX3T Mercedes-Benz Group (ex Daimler) 710000 RENK RENK73 Lufthansa 823212 DroneShield A2DMAA Infineon 623100 Bayer BAY001 BASF BASF11 Porsche PAG911 Deutsche Telekom 555750
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Zoll-Konflikt: DAX geht etwas tiefer ins Wochenende -- Rekorde an der Wall Street -- Intel macht weniger Gewinn -- VW senkt Prognose -- Rheinmetall & Co., Clara Tech, Novo Nordisk, Palantir im Fokus
Top News
Proprietary Trading: So funktioniert der gehebelte Eigenhandel mit Firmenkapital Proprietary Trading: So funktioniert der gehebelte Eigenhandel mit Firmenkapital
Zollstreit zwischen USA und EU: Treffen zwischen von der Leyen und Trump am Sonntag Zollstreit zwischen USA und EU: Treffen zwischen von der Leyen und Trump am Sonntag
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Ãœbersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
25 € Neukundenbonus + 1 Aktie gratis. Hol Dir jetzt Dein finanzen.net ZERO-Depot!

AbbVie Aktie

Handeln
AbbVie Aktien-Sparplan
161,80 EUR -1,20 EUR -0,74 %
BMN
190,47 USD +0,15 USD +0,08 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.286,10 Mrd. EUR

KGV74,34Div. Rendite3,54%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1J84E

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00287Y1091

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolABBV

AbbVie Aktien News

DatumMeistgelesen
PR NewswireAbbVie Announces Reimbursement for VRAYLAR® (cariprazine) for the Treatment of Schizophrenia under the Non-Insured Health Benefits (NIHB) Program
PR NewswireAbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
PR NewswirePhase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus
PR NewswireNew England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease
PR NewswireAbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ® (upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 Congress
PR NewswireEPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
PR NewswireU.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults
PR NewswireHealth Canada Approves AbbVie's RINVOQ® (upadacitinib) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
PR NewswireAbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®
PR NewswireAbbVie to Present at the Bank of America Securities Healthcare Conference
PR NewswireAbbVie Reports First-Quarter 2023 Financial Results
PR NewswireAbbVie Announces Late-Breaking Results from Phase 3 Trial Evaluating Atogepant (QULIPTA®) for the Preventive Treatment of Episodic Migraine Among Patients with Prior Treatment Failure at the 2023 ...
PR NewswireU.S. FDA Approves QULIPTA® (atogepant) for Adults With Chronic Migraine
PR NewswireAbbVie Announces Provincial Reimbursement for VRAYLAR® (cariprazine) for the Treatment of Schizophrenia in Québec
PR NewswireAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Moderately to Severely Active Crohn's Disease
PR NewswireAbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year
PR NewswireAbbVie to Host First-Quarter 2023 Earnings Conference Call
PR NewswireCoolSculpting® Elite Announces First Ever CoolMonth
PR NewswireAllergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023
PR NewswireCIBC introduces additional Canadian Depositary Receipts ("CDRs")
PR NewswireCIBC introduces additional Canadian Depositary Receipts ("CDRs")
PR NewswireAbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus
PR NewswireRisankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis
PR NewswireAbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application
PR NewswireAbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor T...
PR NewswireAbbVie Partners with Award-Winning Redglass Pictures on New Film Shedding Light on the Hidden Struggles of Those Living with Eczema
PR NewswireAbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting
PR NewswireAbbVie to Present at the Barclays Global Healthcare Conference
PR NewswireAbbVie to Present at the Cowen 43rd Annual Health Care Conference
PR NewswireAbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO)
PR NewswireAbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Crohn's Disease
PR NewswireAbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need
PR NewswireAbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need
MyDividendsAbbVie meldet Dividende
PR NewswireAbbVie Declares Quarterly Dividend
PR NewswireAbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
PR NewswireAllergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023
PR NewswireJUVÉDERM® VOLUX™ XC FOR IMPROVEMENT OF JAWLINE DEFINITION NOW AVAILABLE NATIONWIDE
PR NewswireSkinMedica® Launches Even & Correct
PR NewswireAbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets

AbbVie News

AbbVie News: auf dieser Seite finden Sie alle AbbVie News und Nachrichten zur AbbVie Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AbbVie News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AbbVie News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.